VAR - Varian Medical Systems, Inc.

NYSE - NYSE Delayed Price. Currency in USD
104.47
+0.28 (+0.27%)
At close: 4:02PM EDT

104.47 0.00 (0.00%)
After hours: 4:35PM EDT

Stock chart is not supported by your current browser
Previous Close104.19
Open104.53
Bid0.00 x 1800
Ask0.00 x 900
Day's Range103.15 - 105.55
52 Week Range99.00 - 130.29
Volume934,034
Avg. Volume607,592
Market Cap9.564B
Beta (3Y Monthly)0.95
PE Ratio (TTM)67.66
EPS (TTM)1.54
Earnings DateOct 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1998-12-02
1y Target Est120.00
Trade prices are not sourced from all markets
  • PR Newswire5 hours ago

    Varian Ranked First in Probability of Repurchase and Overall Manufacturer, System, and Service Performance in 2018 Survey of Radiation Oncology Professionals

    PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has been ranked first in seven categories, including probability of repurchase, overall manufacturer performance, ...

  • EW, VAR Earnings Due on Oct 23: Here Are Key Predictions
    Zacks9 hours ago

    EW, VAR Earnings Due on Oct 23: Here Are Key Predictions

    Both Edwards Lifesciences (EW) and Varian Medical (VAR) are brimming with prospects despite the current political disarray within the medical instruments space.

  • Cincinnati Children’s, UC Health research 1-second cancer treatment
    American City Business Journals10 hours ago

    Cincinnati Children’s, UC Health research 1-second cancer treatment

    The so-called flash therapy, which is delivered in one to three sessions that each last less than one second, represents a promising new direction in the treatment of cancer.

  • PR Newswireyesterday

    Varian Outlines Strategy for AI-Driven Multimodality Adaptive Radiotherapy Suite

    PALO ALTO, Calif. , Oct. 21, 2018 /PRNewswire/ -- During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian (NYSE: VAR) shared details of its development ...

  • PR Newswireyesterday

    Varian Unveils New Bravos Afterloader System for Brachytherapy Treatments

    PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (VAR) today announced the Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatment and providing greater workflow efficiency. HDR brachytherapy involves delivering radiotherapy by temporarily placing a tiny radioactive source directly into the tumor or other targeted area.

  • PR Newswire2 days ago

    Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons

    Consortium focused on preclinical research, clinical implementation and advocacy PALO ALTO, Calif. , Oct. 20, 2018 /PRNewswire/ -- To expand the encouraging preclinical and translational research already ...

  • PR Newswire2 days ago

    Varian Introduces New ProBeam 360° Proton Therapy System

    PALO ALTO, Calif. , Oct. 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced its new single-room proton therapy system, ProBeam ® 360°. With a 30 percent smaller footprint than the previous system, ...

  • Gauging Analysts’ Views on Varian Stock
    Market Realist5 days ago

    Gauging Analysts’ Views on Varian Stock

    Three of the nine analysts covering Varian Medical Systems (VAR) in October have given the stock “strong buy” ratings, three have given it “hold” ratings, and three have given it “sell” ratings.

  • What to Expect from Varian’s Bottom Line in Q4 2018
    Market Realist5 days ago

    What to Expect from Varian’s Bottom Line in Q4 2018

    Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018 compared to $82.7 million in the fourth quarter of fiscal 2017, a rise of 27.02%. The company’s net income translates to a net income per share of $1.13 in the fourth quarter of fiscal 2018 compared to $0.89 in the fourth quarter of fiscal 2017. Varian Medical Systems generated free cash flow of $340.0 million in fiscal 2017.

  • What to Expect from Varian Medical Systems’ Q4 2018 Earnings
    Market Realist5 days ago

    What to Expect from Varian Medical Systems’ Q4 2018 Earnings

    Varian Medical Systems is focused on the design, manufacture, and commercialization of hardware and software products targeted at treating cancer with radiotherapy, stereotactic radiosurgery, brachytherapy, and stereotactic body radiotherapy. Analysts expect Varian Medical Systems’ revenue to rise 3.69% from $739.0 million in the fourth quarter of fiscal 2017 to $766.26 million in the fourth quarter of fiscal 2018. The upcoming quarter could mark the third consecutive quarter of revenue uptick for Varian after four consecutive quarters of revenue falls.

  • How Varian’s Operational Performance Is Expected to Look in Q4
    Market Realist5 days ago

    How Varian’s Operational Performance Is Expected to Look in Q4

    Varian’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 44.23% and 44.15%, respectively. In comparison, the fiscal 2018 gross margins of its peers Globus Medical (GMED), Stryker (SYK), and Zimmer Biomet Holdings (ZBH) are expected to be 77.01%, 66.27%, and 71.91%, respectively. Varian Medical Systems is expected to incur selling, general, and administrative expenses of $140.77 million in the fourth quarter of fiscal 2018 compared to $51.70 million in the fourth quarter of fiscal 2017, a rise of more than 100%.

  • Varian Medical Systems (VAR) Q4 Earnings Preview: What to Know Ahead of the Release
    Zacks6 days ago

    Varian Medical Systems (VAR) Q4 Earnings Preview: What to Know Ahead of the Release

    Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Varian (VAR) Buys Noona to Boost Oncology Software Services
    Zacks7 days ago

    Varian (VAR) Buys Noona to Boost Oncology Software Services

    Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.

  • Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
    Zacks7 days ago

    Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

    Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.

  • PR Newswire10 days ago

    Varian Expands Cancer Care Portfolio with Noona Healthcare Acquisition

    PALO ALTO, Calif. , Oct. 12, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based, mobile service designed ...

  • Stock Market News For Oct 5, 2018
    Zacks17 days ago

    Stock Market News For Oct 5, 2018

    U.S. stocks closed sharply lower on Thursday as yields on government bonds hits a record high for the second successive day

  • Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care
    Zacks17 days ago

    Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care

    Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.

  • PR Newswire18 days ago

    Varian Signs Educational Partnerships with Reliance Group in India

    PALO ALTO, Calif., Oct. 4, 2018 /PRNewswire/ -- Varian (VAR) today announced it has signed an educational partnership with one of India's leading hospital groups to provide greater access to training in advanced radiotherapy and radiosurgery techniques. The Varian Advanced Clinical School will run courses at the Reliance Group's' Kokilaben Dhirubhai Ambani Hospital (KDAH) in Mumbai, where the region's first Varian Edge™ radiosurgery system was installed in 2016. The clinical school is aimed at radiation oncologists, medical physicists and radiation therapy technologists in India.

  • PR Newswire19 days ago

    Varian Appoints New Division Presidents

    PALO ALTO, Calif., Oct. 3, 2018 /PRNewswire/ -- Varian (VAR), today announced it has appointed Kolleen T. Kennedy, formerly president of Varian Oncology Systems (VOS) to a new role as president of Proton Solutions, the division formerly known as Particle Therapy, and chief growth officer. Chris Toth, formerly president of Global Commercial & Field Operations, will succeed Kennedy as the new president of VOS.

  • PR Newswire21 days ago

    Sterling Cancer Hospital Treats First Patient in India on Varian Halcyon System

    PALO ALTO, Calif., Oct. 1, 2018 /PRNewswire/ -- Varian (VAR) today announced a 75-year-old male with lung cancer was the first patient in India to be treated on the Halcyon™ system at Sterling Cancer Hospital in Gujarat. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The system is well suited to treat cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

  • Varian Shares Vision of a World Without Fear of Cancer
    PR Newswirelast month

    Varian Shares Vision of a World Without Fear of Cancer

    PALO ALTO, Calif., Sept. 20, 2018 /PRNewswire/ -- The phrase "You have cancer" understandably strikes fear into the hearts of millions of patients diagnosed with the disease every year around the world. Varian (VAR) does not believe it is science fiction and has just published a new vision paper, "The Future of Cancer Care: Moving from Promise to Reality," to describe this future state and detail the challenges that must be overcome to realize it. The Future of Cancer Care shows how advances in diagnostics, genomics, precision medicine, immunotherapy, care coordination, artificial intelligence, data analytics, and access to affordable care all play a part in achieving a world without fear of cancer.

  • A Look at Hologic Stock’s Recent Performance
    Market Realistlast month

    A Look at Hologic Stock’s Recent Performance

    On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.

  • PR Newswirelast month

    Dr. Jeff Balser Named to Varian Board of Directors

    PALO ALTO, Calif. , Sept. 12, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Jeffrey R. Balser , MD, PhD, president and chief executive officer at Vanderbilt University Medical Center and ...

  • PR Newswirelast month

    Epic Sciences Announces Completion of $52 Million Series E Financing

    SAN DIEGO, Sept. 12, 2018 /PRNewswire/ -- Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing. "We are extremely pleased to have such a strong and diverse syndicate with leaders from the private payer industry, diagnostic strategics, innovators from the technology space, and best-in-class healthcare crossover investors," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.

  • Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals
    Zackslast month

    Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

    Varian's (VAR) advanced cancer care solution prospects bright in the global market.